Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk Improvement 15% Viral clearance 76% Conv. Plasma  Li et al.  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 103 patients in China (February - April 2020) Improved viral clearance with convalescent plasma (p=0.012) c19early.org Li et al., JAMA, June 2020 Favors conv. plasma Favors control

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Small RCT 103 severe condition patients, 52 treated with convalescent plasma, showing improved viral clearance but no statistically significant improvements in mortality or clinical improvement. ChiCTR2000029757.
risk of death, 34.6% lower, RR 0.65, p = 0.30, treatment 8 of 51 (15.7%), control 12 of 50 (24.0%), NNT 12, odds ratio converted to relative risk, 28 days.
risk of no improvement, 15.3% lower, RR 0.85, p = 0.37, treatment 25 of 52 (48.1%), control 29 of 51 (56.9%), NNT 11, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, 28 days.
risk of no viral clearance, 76.4% lower, RR 0.24, p = 0.01, treatment 4 of 26 (15.4%), control 15 of 23 (65.2%), NNT 2.0, inverted to make RR<1 favor treatment, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 3 Jun 2020, Randomized Controlled Trial, China, peer-reviewed, 34 authors, study period 14 February, 2020 - 1 April, 2020.
This PaperConv. PlasmaAll
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
MD Ling Li, PhD Wei Zhang, MD Yu Hu, PhD Xunliang Tong, PhD Shangen Zheng, MD Juntao Yang, PhD Yujie Kong, MD Lili Ren, PhD Qing Wei, MD Heng Mei, PhD Caiying Hu, MD Cuihua Tao, MD Ru Yang, MD Jue Wang, MD Yongpei Yu, PhD; Yong Guo, Xiaoxiong Wu, MD Zhihua Xu, MD Li Zeng, MD Nian Xiong, Lifeng Chen, MD Juan Wang, MD Ning Man, MD Yu Liu, PhD Haixia Xu, E Deng, MS Xuejun Zhang, MS Chenyue Li, MD Conghui Wang, PhD Shisheng Su, PhD Linqi Zhang, PhD Jianwei Wang, PhD Yanyun Wu, PhD Zhong Liu
JAMA, doi:10.1001/jama.2020.10044
IMPORTANCE Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. OBJECTIVE To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.
References
Alt, median (IQR, U/L
Arabi, Hajeer, Luke, Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia, Emerg Infect Dis, doi:10.3201/eid2209.151164
Ast, median (IQR, U/L
Beigel, Aga, Mc, IRC005 Study Team. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial, Lancet Respir Med, doi:10.1016/S2213-2600(19)30199-7
Cheng, Wong, Soo, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-004-1271-9
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2004168117
Garraud, Heshmati, Pozzetto, Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow, Transfus Clin Biol, doi:10.1016/j.tracli.2015.12.003
Kleinbaum, Evaluating the proportional hazards assumption
Kraft, Hewlett, Koepsell, Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States, Clin Infect Dis, doi:10.1093/cid/civ334
Shen, Wang, Zhao, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, doi:10.1001/jama.2020.4783?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.10044
Soo, Cheng, Wong, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients, Clin Microbiol Infect, doi:10.1111/j.1469-0691.2004.00956.x
Urea Nitrogen, median (IQR
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.10044
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.10044
Yeh, Chiueh, Siu, Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital, J Antimicrob Chemother, doi:10.1093/jac/dki346
Zhang, Tong, Zheng, Yang, Wei et al., Critical revision of the manuscript for important intellectual content
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit